adesso (ADN1) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
11 May, 2026Executive summary
Achieved 13% organic revenue growth year-over-year to EUR 398.1 million in Q1 2026, with all growth organic and no M&A impact.
EBITDA rose 58% to EUR 27.0 million, with margin improving to 6.8% from 4.9%, driven by higher sales and controlled operating expenses.
Net income and EPS improved, with consolidated earnings at EUR 2.7 million and EPS at EUR 0.39, both positive after prior year losses.
Growth was supported by strong demand in insurance, utilities, and public sector, as well as digitalization and SAP projects.
Headcount increased 10% year-over-year to 11,497, with most growth in Germany and significant shoring in Romania, Bulgaria, and India.
Financial highlights
Gross margin remained stable, supporting EBITDA growth, while gross profit per employee increased to EUR 117,000.
Personnel costs per FTE increased 1% due to senior hires and inflation, partially offset by shoring; total staff costs rose 12%.
Net working capital rose 28% year-over-year, contributing to higher net debt, which reached EUR 141.2 million.
Equity ratio improved to 22.0% as of March 2026.
Operating cash flow was negative in Q1, reflecting typical seasonal outflows, but free cash flow remained negative at EUR -64.9 million.
Outlook and guidance
Full-year revenue guidance of EUR 1.6–1.7 billion (9–16% growth) and EBITDA of EUR 130–150 million reaffirmed, with majority of revenue and EBITDA expected in H2.
Capacity utilization expected to improve in Q2 and remain stable, with hiring speed reduced.
Tax rate for the year expected between 45–55%, above normal due to non-deductible expenses and loss-making subsidiaries.
Profitability expected to improve, supported by additional working days and stabilized utilization.
Latest events from adesso
- 2025 sales rose 14% to EUR 1.47B, with 30% EBITDA growth and a strong 2026 outlook.ADN1
Q4 202531 Mar 2026 - Sales up 11% with margin pressure; H2 2025 expected to drive earnings recovery.ADN1
Q1 2025 TU3 Feb 2026 - Sales up 16% to €631.1m, but negative EPS and lower EBITDA guidance due to margin pressure.ADN1
H1 20241 Feb 2026 - Record sales and profitability in Q3 2024, with strong outlook and share buyback underway.ADN1
Q3 2024 TU14 Jan 2026 - Sales, EBITDA, and EPS surged, with robust sector growth and guidance at the upper end.ADN1
Q3 202515 Nov 2025 - 12% sales and 34% EBITDA growth in H1 2025, but free cash flow and equity ratio declined.ADN1
Q2 202518 Aug 2025 - 14% organic growth and margin gains set stage for further expansion in 2025.ADN1
H2 20245 Jun 2025